Dingdang Health Technology Group Ltd. disclosed in a Next Day Disclosure Return (15 June 2026) that it has repurchased a cumulative 8.98 million ordinary shares on the Hong Kong Stock Exchange from 19 May to 15 June 2026. The repurchases, all intended for cancellation but not yet cancelled as of 15 June, were executed at prices ranging from HK$0.82 to HK$0.96 per share, for an estimated aggregate consideration of about HK$8.05 million.

Key data:

• Issued share capital – no immediate change: The company’s issued share count stood at 1,254.65 million shares on both 12 June (opening balance) and 15 June 2026 (closing balance). The repurchased shares remain in the share capital figure until formal cancellation.

• Latest daily transaction: On 15 June 2026, Dingdang Health bought back 33,000 shares on the Exchange at HK$0.91–0.92 each, spending HK$30,261.

• Cumulative repurchases under mandate: Since the 28 May 2025 mandate authorising up to 131.95 million shares for buy-back, Dingdang Health has repurchased 73.80 million shares, equating to 5.59 % of the company’s issued share base on the mandate date. The latest series of buybacks represents roughly 0.72 % of current issued shares.

• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling any treasury shares until 15 July 2026.

All repurchases were executed on the Hong Kong Stock Exchange and, according to the company, complied with applicable listing rules and corporate approvals.